NASDAQ$ARVN

Arvinas Inc. · Q4 2024 earnings

Q4 2024 earnings · · Before market open · Investor relations

Briefing

Arvinas reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a corporate update.

Arvinas reported its Q4 and full year 2024 financial results, highlighting progress across its pipeline, including the upcoming topline data from the VERITAC-2 Phase 3 trial and the initiation of a Phase 1 trial with ARV-102 in patients with Parkinson's disease. The company's cash, cash equivalents, and marketable securities are expected to fund operations into 2027.

  • Topline data from the monotherapy Phase 3 VERITAC-2 trial is anticipated in 1Q25.
  • Phase 1b data from the TACTIVE-U sub-study of vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity.
  • Planned initiation of first-line Phase 3 trial evaluating vepdegestrant in combination with Pfizer’s novel investigational CDK4 inhibitor atirmociclib and a second-line Phase 3 combination trial evaluating vepdegestrant with a CDK4/6 inhibitor, both planned to begin in 2025.
  • Initiated a Phase 1 trial with ARV-102 in patients with Parkinson’s disease and announced Phase 1 data in healthy volunteers has been accepted for oral presentation at Alzheimer’s Disease/Parkinson’s Disease congress.

Headline financials

Total Revenue

$59.2M

Previous: -$43.1M+237.4%
EPS (adj)

-$0.63

Previous: -$2.53+75.1%
R&D Expenses

$69.5M

No prior period
G&A Expenses

$19.2M

No prior period
Net Income

-$45.1M

Previous: -$155M+70.9%
Operating Income

-$58.2M

Previous: -$165M+64.8%

Revenue & EPS history

Arvinas · Revenue · Quarterly

$59.2M

Q4 2024-237.4%vs Q4 2023
Beat estimate in 9 of 14 quarters(64%)
ActualEstimate

Revenue by segment

Arvinas · $30.3M total across 1 segment · Q3 2022

  • Collaboration Revenue
    $30.3M+225.8%

Forward guidance

Arvinas anticipates several milestones including topline data from VERITAC-2, initiation of Phase 3 combination trials, and data presentations for ARV-393 and ARV-102. The company believes its current cash is sufficient to fund operations into 2027.

Tailwinds

  • Announce topline data for the VERITAC-2 Phase 3 monotherapy clinical trial evaluating vepdegestrant in patients with ER+/HER2- metastatic breast cancer (mBC) in a topline press release 1Q25 and present full results of the trial at a medical conference in 2025.
  • Initiate two new Phase 3 combination trials in patients with ER+/HER2- mBC (pending emerging data and regulatory feedback) in 2025: First-line Phase 3 combination trial with Pfizer’s novel investigational CDK4 inhibitor, atirmociclib. Second-line Phase 3 combination trial with a CDK4/6 inhibitor.
  • Continue to collect safety and efficacy data from ongoing TACTIVE-U sub-studies evaluating combination of vepdegestrant with abemaciclib, ribociclib, or samuraciclib (ClinicalTrials.gov Identifiers: NCT05548127, NCT05573555, and NCT06125522) and submit key data for presentation at medical conference.
  • Continue enrollment in the Phase 2 TACTIVE-K clinical trial (atirmociclib + vepdegestrant) and submit initial Phase 1b data for presentation at a medical conference.
  • Present preclinical data of ARV-393 in combination with standard of care biologic agents and small molecule inhibitors in high grade and aggressive diffuse large B-cell lymphoma in vivo models at the American Association for Cancer Research Annual Meeting (April 25-30, 2025).

Headwinds

  • The VERITAC-3 Phase 3 clinical trial evaluating vepdegestrant plus palbociclib in the first-line will not proceed beyond the study lead-in.
  • Potential risks and uncertainties related to the performance of obligations under the collaboration between Arvinas and Pfizer.
  • Risks related to the successful conduct and completion of clinical development for vepdegestrant and other product candidates.
  • Uncertainties regarding the ability to obtain marketing approval for and commercialize vepdegestrant and other product candidates.
  • Risks associated with Arvinas' ability to protect its intellectual property portfolio and reliance on third parties.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q4 2024

Historical avgQ4 2024

-2.4%

Avg return

Earnings day

-2.1%

Avg return

5 days after

-0.6%

Avg return

30 days after

30%

9 / 30 earnings

Positive

+11.8%

Q1 2019

Best reaction

-24.8%

Q1 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-4.4%-10.2%
Q4 2025+5.2%+4.7%-7.4%
Q3 2025+0.5%+17.3%+34.1%
Q1 2025-24.8%-27.8%-25.2%
Q4 2024-6.8%-3.5%-54.9%
Q3 2024-3.9%-2.5%-2.8%
Q2 2024-1.0%-7.0%-6.3%
Q1 2024+0.3%-2.5%-14.1%
Q4 2023-5.8%-3.1%-15.4%
Q3 2023-2.5%-11.5%+93.1%
Q2 2023+2.1%+6.8%+12.8%
Q1 2023+4.9%+3.0%-1.2%
Q4 2022-7.0%-10.8%-23.0%
Q3 2022-4.0%+17.9%-12.5%
Q2 2022+3.8%+4.5%-19.3%
Q1 2022-16.4%-22.6%-19.0%
Q4 2021-2.6%-4.4%-5.4%
Q3 2021+4.9%+1.2%-18.8%
Q2 2021-4.3%-8.9%-13.4%
Q1 2021-4.0%-9.1%-1.7%
Q4 2020-1.0%-8.0%-15.6%
Q3 2020-3.6%+4.3%+18.6%
Q2 2020-5.0%-11.1%-23.0%
Q1 2020-0.9%-6.0%-17.7%
Q4 2019-3.2%-1.8%+14.2%
Q3 2019+3.3%+17.6%+79.4%
Q2 2019-4.6%-0.2%-1.5%
Q1 2019+11.8%+11.1%+0.8%
Q4 2018-3.0%-6.9%+42.9%
Q3 2018-0.1%+7.3%-13.6%
Q2 2018
Q1 2018
Q4 2017
Q3 2017
Q2 2017
Q1 2017

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro